-
MAPK10–KRT16 Axis in NSCLC Metastasis
2026-09-02
A 2026 study identifies MAPK10 as a metastasis-suppressive kinase that phosphorylates KRT16 at Ser356 and Ser397, enabling RNF213-mediated ubiquitination and proteasomal degradation. The findings connect kinase activity with cytoskeletal protein turnover and suggest a prognostic MAPK10/KRT16/RNF213 axis, while also defining important limits for therapeutic translation.
-
Rotigotine and Antidepressant-Like Effects in Rats
2026-09-02
The 2006 reference study evaluated rotigotine across anxiety, behavioral despair, learned helplessness, and olfactory bulbectomy models, showing antidepressant-like activity at doses that did not consistently increase baseline locomotion. Its main contribution is a dose- and paradigm-sensitive framework for separating potential mood-related effects from nonspecific motor stimulation, which remains relevant to dopaminergic signaling research and Parkinson’s disease research.
-
Camostat Mesilate: From ENaC to Fibrosis
2026-09-01
Camostat Mesilate is a trypsin-like protease inhibitor with a distinctive research profile spanning ENaC function, plasmin activity, TGF-β signaling, and hepatic fibrosis. This guide translates those mechanisms into a layered assay strategy and compares it with structure-guided proteomimetic design.
-
Ginsenosides and PHD2/HIF-1α Signaling in Hypoxia
2026-09-01
This study tests whether ginsenosides protect lung and kidney tissue during simulated high-altitude hypoxia and links the phenotype to PHD2/HIF-1α/EPO signaling. Its integrated physiological, histological, inflammatory, oxidative-stress, and protein-expression readouts provide a useful framework for evaluating tissue protection while leaving causal and translational questions open.
-
Pioglitazone: PPARγ Agonist Research Workflows
2026-08-31
Translate selective PPARγ activation into reproducible macrophage, beta-cell, metabolic, and neuroinflammation assays. This practical guide combines reference-backed DSS intestinal inflammation findings with formulation, controls, readout, and troubleshooting strategies for Pioglitazone research.
-
Hyperoxia, Nrf2, and Intestinal Ferroptosis
2026-08-31
Liu et al. show that hyperoxia-associated intestinal oxidative injury involves ferroptosis and is linked to Nrf2 regulation and the COX-2/PGE2/EP2 inflammatory pathway. The study provides a mechanistic framework for connecting redox imbalance, mitochondrial damage, epithelial injury, and inflammation in neonatal hyperoxia models.
-
Alfuzosin Hydrochloride: Assay Workflow Guide
2026-08-30
A scenario-driven laboratory guide to using Alfuzosin Hydrochloride (SKU A5173) in cell viability, proliferation, smooth-muscle, and α1-adrenergic signaling studies. It connects solvent selection, analytical linearity, endpoint interpretation, and vendor evaluation to improve experimental comparability without overstating what in vitro data can establish.
-
Acetylcholine Chloride: Designing Causal Assays
2026-08-29
Acetylcholine Chloride provides a controllable way to interrogate acetylcholine neurotransmitter signaling from receptor activation to gut–vagus–brain circuit function. This article translates recent Bacteroides fragilis epilepsy findings into practical assay-design decisions without treating an exogenous chemical stimulus as a substitute for endogenous physiology.
-
LDN-193189: Selective ALK Inhibitor for BMP Research
2026-08-28
LDN-193189 is a selective BMP type I receptor ALK inhibitor that targets ALK2 and ALK3 and suppresses Smad1/5/8, p38 MAPK, and Akt signaling. Its documented research uses include BMP pathway studies, epithelial barrier function protection, and heterotopic ossification research, but it is not an antiviral or medical treatment.
-
Direct Mouse Genotyping Kit for Assay Reliability
2026-08-28
Learn how the Direct Mouse Genotyping Kit, SKU K1025, can reduce genotype-assignment delays before mouse viability, proliferation, and cytotoxicity studies. This scenario-based guide covers compatibility, protocol handling, interpretation, and practical vendor-selection criteria without overstating performance beyond the available product evidence.
-
Ellagic Acid for CK2 and Senescence Assays
2026-08-27
Ellagic acid provides a practical CK2 perturbation tool for connecting kinase biochemistry with cancer biology research, apoptosis research, and oxidative stress assay design. This guide covers solvent handling, concentration planning, orthogonal validation, and a cautious strategy for exploring senescence-related selectivity without overstating the evidence.
-
Rotigotine in Parkinson’s Disease Research
2026-08-27
Rotigotine is a dopamine D2/D3 receptor agonist suited to experiments that connect receptor activation with motor, oxidative-stress, inflammatory, and non-motor outcomes. This guide converts its formulation properties and exposure ranges into practical cell-based, animal-model, and translational workflows.
-
PPACK Dihydrochloride: Assay Logic for Thrombin
2026-08-26
PPACK Dihydrochloride enables precise separation of thrombin-dependent effects from platelet purinergic signaling. This guide combines covalent inhibition chemistry with insights from NF449 studies to improve assay design, controls, and interpretation in blood coagulation research.
-
Perphenazine and Prochlorperazine in Melanoma Cells
2026-08-26
The reference study evaluated two phenothiazine derivatives in melanotic COLO829 and amelanotic C32 melanoma cells, combining viability, motility, MITF, and tyrosinase measurements. Its main contribution is evidence that prochlorperazine can suppress melanoma-associated phenotypes in vitro, particularly in amelanotic cells, while also showing that responses depend on melanoma cell state.
-
Grazoprevir/Elbasvir Therapy for HCV: Evidence
2026-08-25
The reference review evaluates an interferon-free, fixed-dose combination that pairs the NS3/4A protease inhibitor grazoprevir with the NS5A inhibitor elbasvir. Its main contribution is to integrate efficacy, safety, resistance, and subgroup evidence showing why dual-target therapy became a practical strategy for broad HCV management.